DAVID LYNN COOPER
Pilots at Smoking Oaks Dr, Oklahoma City, OK
License number
Oklahoma A2264265
Issued Date
Mar 2017
Expiration Date
Mar 2018
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
11721 Smoking Oaks Dr, Oklahoma City, OK 73150
Professional information
Methods And Compositions For Attenuating Antibody-Mediated Xenograft Rejection In Human Recipients
US Patent:
6607723, Aug 19, 2003
Filed:
Jun 2, 1995
Appl. No.:
08/458683
Inventors:
A. Heather Good - Edmonton, CA
David K.C. Cooper - Oklahoma City OK
Andrew J. Malcolm - Edmonton, CA
David K.C. Cooper - Oklahoma City OK
Andrew J. Malcolm - Edmonton, CA
Assignee:
Alberta Research Council - Edmonton
Integris Baptist Medical Center, Inc. - Oklahoma City OK
Integris Baptist Medical Center, Inc. - Oklahoma City OK
International Classification:
A61K 34385
US Classification:
4241401, 435 721, 435 725, 530413, 536 41, 536 172, 536 221, 536 552
Abstract:
Antibody-mediated xenograft rejection is attenuated by (1) removing preformed antibodies to various identified carbohydrate xenoantigens from the recipients circulation prior to transplantation by extracorporeal perfusion of the recipients blood over a biocompatible solid support to which the xenoantigens are bound and/or (2) parenterally administering a xenoantibody-inhibiting amount of an identified xenoantigen to the recipient shortly before graft revascularization and thereafter.
Genetically Engineered Animals For Use As Organ Donors
US Patent:
2002015, Oct 17, 2002
Filed:
Sep 4, 2001
Appl. No.:
09/946034
Inventors:
David Cooper - Oklahoma City OK, US
Eugen Koren - Oklahoma City OK, US
Eugen Koren - Oklahoma City OK, US
Assignee:
Baptist Medical Center of Oklahoma, Inc.
International Classification:
A01K067/027, A61K048/00, C12N005/06
US Classification:
800/014000, 424/093210, 435/325000
Abstract:
Methods to manipulate animals such as pigs, and the animals and tissues thereby derived, to reduce their immunogenicity following implantation into humans, are described. These methods are based on the discovery that certain carbohydrate structures on pig tissues, which require expression of the gene encoding the 1→3 galactosyl transferase enzyme, are targets for natural preformed antibodies of humans and elicit further antibody production in humans, while other carbohydrate structures do not or do so in a reduced amount. In the preferred embodiment, animals are produced by homologous recombination of the gene encoding 1→3 galactosyl transferase in embryonic stem cells or by microinjection into embryos of sequences eliminating or decreasing expression of 1→3 galactosyl transferase. In alternative embodiments, animals are produced having reduced amounts of 1→3 galactosyl epitopes or epitopes which are masked by sialylation or fucosylation.
Genetically Engineered Animals For Use As Organ Donors
US Patent:
2003013, Jul 10, 2003
Filed:
Jun 12, 2002
Appl. No.:
10/172459
Inventors:
David Cooper - Oklahoma City OK, US
Eugen Koren - Oklahoma City OK, US
Eugen Koren - Oklahoma City OK, US
Assignee:
INTEGRIS Baptist Medical Center, Inc.
International Classification:
A01K067/027
US Classification:
800/014000
Abstract:
Methods to manipulate animals such as pigs, and the animals and tissues thereby derived, to reduce their immunogenicity following implantation into humans, are described. These methods are based on the discovery that certain carbohydrate structures on pig tissues, which require expression of the gene encoding the 1→3 galactosyl transferase enzyme, are targets for natural preformed antibodies of humans and elicit further antibody production in humans, while other carbohydrate structures do not or do so in a reduced amount. In the preferred embodiment, animals are produced by homologous recombination of the gene encoding 1→3 galactosyl transferase in embryonic stem cells or by microinjection into embryos of sequences eliminating or decreasing expression of 1→3 galactosyl transferase. In alternative embodiments, animals are produced having reduced amounts of →1→3 galactosyl epitopes or epitopes which are masked by sialylation or fucosylation.
Compositions For Attenuating Antibody- Mediated Xenograft Rejection In Human Recipients
US Patent:
5977079, Nov 2, 1999
Filed:
Sep 23, 1997
Appl. No.:
8/935637
Inventors:
A. Heather Good - Edmonton, CA
David K.C. Cooper - Oklahoma City OK
Andrew J. Malcolm - Edmonton, CA
David K.C. Cooper - Oklahoma City OK
Andrew J. Malcolm - Edmonton, CA
Assignee:
Alberta Research Council Edmonton
Integris Baptist Medical Center, Inc. - Oklahoma City OK
Integris Baptist Medical Center, Inc. - Oklahoma City OK
International Classification:
A61K 3170, C07H 1500
US Classification:
514 25
Abstract:
Antibody-mediated xenograft rejection is attenuated by (1) removing preformed antibodies to various identified carbohydrate xenoantigens from the recipient's circulation prior to transplantation by extracorporeal perfusion of the recipient's blood over a biocompatible solid support to which the xenoantigens are bound and/or (2) parenterally administering a xenoantibody-inhibiting amount of an identified xenoantigen to the recipient shortly before graft revascularization and thereafter.